Slide 1 of 1 
Equine IFN alpha 1 Recombinant Protein
- Catalog Number:
- RP0142E
- Availability:
- In stock
- Application:
- Cell Culture, ELISA Standard, ELISpot Control, Western Blot Control
- 100% Homology:
- Equus caballus (horse)
- Equine IFN-α1 (catalog RP0142E) is a yeast-derived cytokine supplied lyophilized without carrier protein in 10% trehalose; it has no affinity tags and is naturally endotoxin-free, and should be reconstituted in sterile PBS that contains at least 0.1% carrier protein. The protein is ~18.5 kDa, 161 amino acids long (full sequence provided), and >98% pure by SDS-PAGE, with 100% amino-acid homology to horse. Store at -20°C (stable up to twelve months from date of receipt; working aliquots with carrier protein stable at least 3 months) and avoid repeated freeze/thaw cycles. Product origin is the USA. Kingfisher Biotech products are supplied for research applications and are not intended for medicinal, diagnostic, or therapeutic use. It is commonly used to study interferon-α signaling and antiviral responses, induction of interferon-stimulated genes and antiviral states, and for antiviral/cytopathic-effect assays; typical experimental uses include cell-culture stimulation and dosing studies, ELISA and neutralization assays, receptor-binding studies, flow-cytometry and Western blot controls, and antibody generation/validation.
| Amino Acid Sequence | CDLPHTHSLG NTRVLMLLGQ MRRISPFSCL KDRNDFGFPQ EVFDGNQFRK PQAISAVHET IQQIFHLFST DGSSAAWDES LLDKLYTGLY QQLTELEACL SQEVGVEETP LMNEDSLLAV RRYFQRIALY LQEKKYSPCA WEIVRAEIMR SFSSSTNLPQ S (161) |
| Endotoxin | Naturally endotoxin-free |
| Storage Conditions | -20°C |
| Molecular Weight | 18.5 kDa |
| Purity | >98% as visualized by SDS-PAGE analysis. |
| Country Of Origin | USA |
- Equine Interferon-Alpha (IFN-α) is a type I interferon produced primarily by plasmacytoid dendritic cells and virus-infected epithelial and immune cells in horses (Equus caballus), where it plays a central role in early innate antiviral defense. Upon binding to the type I interferon receptor complex (IFNAR1/IFNAR2), equine IFN-α activates JAK/STAT signaling pathways, leading to induction of interferon-stimulated genes (ISGs) that inhibit viral replication, enhance antigen presentation, and promote activation of natural killer (NK) cells and adaptive immune responses. IFN-α is rapidly upregulated in response to important equine viral pathogens such as equine influenza virus, equine herpesvirus-1 and -4 (EHV-1/EHV-4), West Nile virus, and equine arteritis virus, where it contributes to viral control but may also influence inflammatory pathology if dysregulated. Modulation of type I interferon responses can affect disease severity, viral shedding, and vaccine responsiveness. In veterinary and translational research, characterization of equine IFN-α supports studies of respiratory viral pathogenesis, neuroinvasive viral disease (e.g., EHV-1 and West Nile virus), antiviral therapeutic development, and comparative type I interferon biology in large-animal systems relevant to both equine health and broader immunological research.
Please choose a size to see price
RELATED MEDIA
